The role of anthracyclines/anthraquinones in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 81, Issue SUPPL. 1, 2003, Pages

  Beslija, Semir ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

Anthracyclines anthraquinones; Chemotherapy; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FLUOXYMESTERONE; METHOTREXATE; MITOXANTRONE; PREDNISONE; TAMOXIFEN;

ACUTE HEART FAILURE; ALOPECIA; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAVASATION; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; META ANALYSIS; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MYOCARDITIS; NAUSEA; PERICARDITIS; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

EID: 0344441841     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1026308604784     Document Type: Conference Paper

References (58)

1. Shank, Lincof AM, Young JB: Anthracycline induced cardiotoxicity. Ann Int Med 125: 930-942, 1996
2. Smylie M: Liposomal doxorubicin in the treatment of metastatic breast cancer. In: Nabholtz JM, Tonkin K, Aapro MS et al. (eds) Breast Cancer Management. Martin Duntiz, London, 2000, p 99
3. Ellis MJ, Hayes DF, Lippman ME: Treatment of metastatic breast cancer. In: Harris JR, Lippman ME, Morrow M et al. (eds) Diseases of the Breast. Lippincott Williams & Wilkins, Philadelphia, 2000, p 749
4. Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimen. Br J Cancer 67: 801-805, 1993
5. Fossati R, Confalonieri C, Torri V et al.: Cytotoxic and hormonal treatment for metastatic breast cancer. A systematic review of published randomized trials involving 31510 women. J Clin Oncol 10: 3439-3460, 1998
6. 2 DI, 8 prolongs time to progression (TTP) with respect to I.V. CMF DI, 8 given at equimyelosuppressive doses as front line chemotherapy of metastatic breast cancer (MBC): a randomized multinational multicentric phase III trial. Proc AM Soc Clin Oncol 14: 114a, 1995 (abstract #156)
7. Andersson M, Medsen EL, Overgaard M et al.: Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer - a randomized study with more than 10 years follow-up from the Danish Breast cancer Cooperative Group. Eur J Cancer 35: 39-46, 1999
8. Rahman ZU, Frye DK, Smith TL et al.: Result and long term follow-up for 1851 patients with metastatic breast carcinoma treated with standard dose doxorubicin containing chemotherapy: a reference. Cancer 85: 104-111, 1999
9. Signal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905, 1998
10. Lefrak EA, Pitha J, Rosenheim S et al.: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32: 302-314, 1973
11. Bristow MR, Billingham ME, Mason JW et al.: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62: 873-879, 1978
12. Ormrod D, Holm K, Goa K et al.: Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. Drugs Aging 15: 389-416, 1999
13. Launchbury AP, Habboubi N: Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19: 197-228, 1993
14. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. J Clin Oncol 6: 679-688, 1988
15. Phase III randomized study of fluorouracil, epirubicin and cyclophophamide versus fluorouracil, doxorubicin and cyclophophamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with epirubicin. J Clin Oncol 6: 976-982, 1988
16. Lopez M, Papaldo P, Di Lauro L et al.: 5-Fluorouracil, adriamycin, cyclophophamide (FAC) versus 5-fluorouracil, epirubicin, cyclophophamide (FEC) in metastatic breast cancer. Oncology 46: 1-5, 1989
17. Heidemann E, Steinke B, Hartlapp J et al.: Randomized clinical trial comparing mitoxantrone with epirubicin and doxorubicin, each combined with cyclophophamide in the firs-line treatment of patients with metastatic breast cancer. Onkologie 13: 24-27, 1990
18. Lawton PA, Spittle MF, Ostrowski MJ et al.: A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma. Clin Oncol 5: 80-84, 1993
19. Gasparini D, Dal Fior S, Panizzoni GA et al.: Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized Clinical trial. Am J Clin Oncol 14: 38-44, 1991
20. Castiglione M, Schatzmann E, Goldhirsh A et al: Adriamycin (A) versus epirubicin (E): low dose weekly schedule in metastatic breast cancer. Preliminary results of tumor response and of quality-of-life measurements. Proc Am Soc Clin Oncol 9: 48a, 1990 (abstract #182)
21. Findlay BP, Walker-Dilks C: Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Cancer Prev Control 2: 140-146, 1998
22. Ardizzoni A, Venturini M, Sertoli MR et al.: Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. Br J Cancer 69: 385-391, 1994 (Medline)
23. Venturini M, Del Mastro L, Testore F et al.: Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer. Cancer Chemother Pharmacol 38: 487-494, 1996 (Medline)
24. Del Mastro L, Garrone O, Sertoli MR et al.: A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer. Eur J Cancer 30A: 606-610, 1994
25. Hryniuk WM, Bush H: The importance of dose-intensity in the outcome of chemotherapy. Important Adv Oncol 121-141, 1988
26. Miller AB, Hoogstraten B, Staquet M et al.: Reporting results of cancer treatment. Cancer 47: 207-214, 1981 (Medline)
27. Schabel Jr FM, Griswold DP, Corbett TH et al.: Increasing the therapeutic response rate to anticancer drugs by applying the basic principles of pharmacology. Cancer 50: 1160-1167, 1980
28. Stadtmauer EA, O'Neill A, Goldstein LJ et al.: Conventional dose chemotherapy compared with high dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 342: 1069-1076, 2000 (abstract/full text)
29. Focan C, Andien JM, Closon MT et al.: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11: 1253-1263, 1993
30. French Epirubicin Study Group: A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 9: 305-312, 1991 (abstract)
31. 2) in the FEC regimen significantly increases response rate. An international randomised phase III study in metastatic breast cancer. Ann Oncol 8: 155-162, 1997 (Medline)
32. Marschner N, Krelenberg R, Souchon R et al.: Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial. Semin Oncol 21(Suppl 1): 10-16, 1994
33. Bastholt L, Dalmark M, Gjedde B et al.: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish breast cancer cooperative group. J Clin Oncol 14: 1146-1155, 1996 (abstract)
34. Venturini M, Bruzzi P, Del Mastro L et al.: Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 14: 764-773, 1996 (abstract)
35. Fountzilas G, Athanassiades A, Giannakakis T et al.: A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer: a Hellenic Cooperative Oncology Group study. Ann Oncol 8: 1213-1220, 1997 (Medline)
36. Del Mastro L, Venturini M, Lionetto R et al.: Accelerated-intensified cyclophophamide, epirubicin and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo group. J Clin Oncol 19: 2213-2221, 2001 (abstract/free full text)
37. Savarese DMF, Hsieh C, Stewart MF: Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 15: 2981-2995, 1997 (Abstract)
38. Biganzoli L, Piccart MJ; The bigger the better? ... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer. Ann Oncol 8: 1177-1182, 1997 (Medline)
39. Chlebowski RT, Smalley RV, Weiner JM et al.: Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and the Southeastern Cancer Study Group. Br J Cancer 59: 227-230, 1989 (Medline)
40. Carmo-Pereira J, Costa O, Henriques E et al.: Single drug versus combination cytotoxic chemotherapy in advanced breast cancer: a randomized study. Eur J Cancer 16: 1621-1625, 1980 (Medline)
41. Ahman DL, Schaid DJ. Bisel HF et al.: The effect on survival of initial chemotherapy in advanced breast cancer. Polychemotherapy versus single drug. J Clin Oncol 12: 1928-1932, 1987
42. Canellos G, Pocock SJ, Taylor SG et al.: Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with α-phenylalanin mustard. Cancer 38: 1882-1886, 1976 (Medline)
43. Joensuu H, Holli K, Heikkinen M: Combination chemotherapy versus single-agent therapy as first-and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 16: 3720-3730, 1998 (Abstract)
44. Heidemann E, Stoeger H, Souchon R et al.: Is first line single agent mitoxantrone in the treatment of high risk metastatic breast cancer patients as affective as combination chemotherapy? No difference in survival but high quality of life were found in a multicenter randomised trial. Ann Oncol 13: 1717-1729, 2002 (Medline)
45. Gregory RK, Powles TJ, Chang JC et al.: A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 33: 2194-2197, 1997 (Medline)
46. Muss HB, Case LD, Richards II F et al.: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 325: 1342-1348, 1991 (Abstract)
47. Coates A, Gebski V, Bishop JF et al.: Improving the quality of life during chemotherapy for advanced breast cancer: A comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490-1495, 1987 (Abstract)
48. Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of dose intensity and duration of treatment. J Clin Oncol 18: 2197-2205, 2000
49. Greenberg PAC, Hortobagyi GN, Smith TL et al.: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197-2205, 1996 (Abstract)
50. Falkson G, Gelman RS, Pandya KJ et al.: Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16: 1669-1676, 1998 (Absract)
51. Ejlertsen B, Pfeiffer P, Pedersen D et al.: Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment from 18 to 6 months. J Cancer 29: 527-531, 1993
52. Neidhart JA, Gochnour D, Roach R, Hoth D, Young D: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4: 627, 1986
53. Hortobagyi GN, Yap HY, Kau SW et al.: A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 12: 57, 1989
54. Henderson IC, Allegra JC, Woodcock T et al.: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560, 1989
55. Bennett JM, Muss HB, Doroshow JH et al.: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 6: 1611, 1988
56. Hausmaninger H, Lehnert M, Steger G et al.: Randomised phase II study of epirubicin-vindesine versus mitoxantronevindesine in metastatic breast cancer. Eur J Cancer 31A: 2169, 1995
57. Pavesi L, Preti P, Da Prada G, Pedrazzoli P, Poggi G, Robustelli della Cuna G: Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer. Anticancer Res 15, 1995
58. Ehninger G, Weible KH, Heidemann E et al.: Mitoxantrone and cyclophosphamide therapy in patients with advanced breast cancer. Cancer Treat Rep 68: 1283-1284, 1984 (Medline)